In the Spotlight

• NovaMedica Launches Own Innovative Drug for the Treatment of Alzheimer’s Disease

  19 April 2022

  

  Russian pharmaceutical company NovaMedica (investment project of RUSNANO) has developed and registered an innovative combination of Donepezil and Memantine molecules, which are the basic therapy for dementia associated with Alzheimer's disease. The drug is registered under the name MIOREOL®. This is the first such combination in the Russian market and in the markets of the EAEU and Europe.

• NovaMedica signed an agreement with Bayer on transfer of exclusive rights to its product

  31 May 2021

  

  Russian pharmaceutical company NovaMedica (part of the RUSNANO portfolio) and the corporation Bayer signed an agreement to provide Bayer with an exclusive license to commercialization of an innovative product developed by NovaMedica, including its manufacturing and promotion.

• R&D Center NovaMedica Innotech joined Avifavir production efforts in Russia

  04 March 2021

  

  R&D Center NovaMedica Innotech (subsidiary of the pharmaceutical company NovaMedica, investment project of RUSNANO) announced release of the first commercial batch of the anti-COVID drug Avifavir® under the partnership with Kromis LLC, joint venture of the Russian Direct Investment Fund (RDIF) and the company ChemRar. NovaMedica Innotech will manufacture 100,000 units of Avifavir per month.

• "So, what is a pill made of?"

  03 March 2021

  

  We have already made a tradition of guided tours to the R&D Center NovaMedica Innotech for our most curious and precious visitors – children who come to see what their mothers and fathers do at work.

• NovaMedica and UNIPHARM to localize the production of Melaxen in Russia at the capacities of the R&D Center NovaMedica Innotech

  25 July 2019

  

  Russian pharmaceutical company NovaMedica and US-based Unipharm have launched a joint project to localize in Russia the production of Melaxen®, a drug that improves the sleep/wake cycle. Volumes are expected to reach hundreds of thousands of units per year, which will be sufficient to fully meet the needs of patients living in the territory of the EAEU.

• NovaMedica and Pharmsynthez agreed to establish full-cycle manufacturing of several in-demand products in Russia

  17 June 2019

  

  Russian pharmaceutical companies NovaMedica and Pharmsynthez started implementing a joint project to ensure access to a number of effective products, with the full manufacturing cycle localized in Russia, for Russian patients within 1.5-2 years. The products are in the anesthesiology and gastroenterology therapeutic areas, intended for both the hospital and commercial markets.

• PharmNews: NovaMedica Innotech debuts on CPhI

  09 October 2018

  

  The international exhibition CPhI has started in Madrid. And today NovaMedica Innotech is in our focus as the company that has made a bright debut at the exhibition. This Technological Center has launched in April 2017 and Moscow Mayor Sergei Sobyanin attended the opening ceremony.

• Five senior managers of NovaMedica were named among the nominees of the Top-1000 Russian Managers rating list for 2018

  25 September 2018

  

  In 2018 Alexander Kuzin, General Director of NovaMedica, was ranked among the most recognized senior managers in the pharmaceutical industry for the fifth time in the rating list. Maria Makarova, Deputy General Director and Vice-President for Finance; Marina Aivazova, Vice-President for Personnel Management and Administrative Matters; Yulia Sobakina, Vice-President for Commerce and Marketing; Tatiana Albaut, PR Director were also included into this competent rating.

• NovaMedica, a portfolio company of RUSNANO, has concluded the biggest SPIC for creation of a greenfield pharmaceutical manufacturing facility in the pharmaceutical industry

  07 March 2018

  

  Russian pharmaceutical company NovaMedica (investment project of Rusnano), Ministry of Industry and Trade of the Russian Federation and Government of the Kaluga Region have concluded Special Investment Contract (SPIC). Denis Manturov, Minister of the Ministry of Industry and Trade, Anatoly Artamonov, Governor of the Kaluga Region, and Alexander Kuzin, General Director of NovaMedica, signed the contract. Arkady Dvorkovich, Deputy Chairman of the Government of the Russian Federation, and Anatoly Chubais, Chairman of the Executive Board of Managing Company “RUSNANO”, were present during the ceremony. SPIC envisages creation of a greenfield facility for manufacturing of sterile injectable dosage forms in the Kaluga region.

• R&D Center of NovaMedica has received GMP-Certificate from the Ministry of Industry and Trade of the Russian Federation

  26 December 2017

  

  Russian pharmaceutical company NovaMedica, investment project of Rusnano, informed about receipt of conclusion of the Ministry of Industry and Trade of the Russian Federation over compliance of the facility of the R&D Center of NovaMedica Innotech (subsidiary of NovaMedica) with the Russian standards of the Good Manufacturing Practice (GMP). The certificate issued basing on the integrated audit of the MIT RF commission, proves that the processes of development, manufacturing and quality control at NovaMedica Innotech are organized in accordance with the high standards of quality and manufacturing of tablets, soft and hard gelatin capsules and pellets at its manufacturing facilities meet the Russian GMP requirements.